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Abstract
Background: Papillary fibroelastoma (PFE) is a rare primary cardiac neoplasm that is usually discovered incidentally
at autopsy or during cardiac surgery. PFE combined with rheumatic heart disease (RHD) is extremely rare, and only
a few cases have been reported. Additionally, the growth rate of the tumor is unknown.
Case Presentation: Here, we present a very rare case of PFE of the aortic valve combined with RHD, which were
identified in a female patient who survived for 5 years without surgical intervention, and who subsequently
underwent successful surgical treatment.
Conclusions: PFEs may be generally slow-growing tumors, however, the better treatment of choice may be
surgery because it produces good curative effects with very low risk of complications, while preventing serious
disease consequences.
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Background
Although papillary fibroelastoma (PFE) is rare, it is the
second most common primary cardiac neoplasm,
accounting for 4.4 % to 8 % of all tumors of the heart
[1]. PFE is usually discovered incidentally at autopsy or
during cardiac surgery. With the advent of higher-
resolution imaging technologies, especially transesopha-
geal echocardiography, cases of PFE are being recognized
more frequently [2]. However, the etiology of PFE and the
time that it takes to develop are both unknown.
Here, we present the case of a 55-year-old female pa-
tient who had a PFE of the aortic valve in combination
with rheumatic heart disease (RHD). She was diagnosed
with RHD in 2010. Although transthoracic echocardiog-
raphy revealed a mass on the non-coronary cusp at that
time, the patient initially refused surgery for economic
reasons. A surgical intervention was ultimately per-
formed 5 years later. In the intervening time, she did not
develop any symptoms related to the PFE, which did not
grow significantly. We view this case as being instructive,
both because PFE rarely appears in combination with
RHD, and because few clinicians are able to observe the
natural history of surgically untreated PFE over such a
long interval of time.
Case Presentation
A 50-year-old woman was first admitted to our hospital
in 2010, when transthoracic echocardiography (TTE)
revealed a mass on the non-coronary cusp for the first
time (Fig. 1), and electrocardiogram showed sinus rhythm.
The patient had valvular heart disease that required sur-
gery, which we strongly recommended as the measure to
treat the disease as well as to confirm the diagnosis of the
mass. However, the patient refused, mainly because of
economic reasons. During the five subsequent years, we
were unable to contact the patient until she returned
in 2015.
In 2015, the 55-year-old woman who had a New York
Heart Association (NYHA) functional class of III was
admitted with the diagnosis of RHD presented as exer-
tional shortness of breath (duration, 6 years) accompanied
by occasional palpitations and dizziness. The patient de-
nied any chest pain, orthopnea, or paroxysmal nocturnal
dyspnea. She denied any history of cardiac tumors,
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coronary artery disease, pulmonary disease, or cancer, as
well as smoking, alcohol consumption, or use of illicit
drugs. Physical examination showed blood pressure of
130/65 mmHg, temperature of 36.7 °C, and heart rate of
76 beats/min. Findings of chest radiography were normal,
while electrocardiography detected atrial fibrillation. The
results of routine blood laboratory investigations were
unremarkable. TTE revealed moderate mitral stenosis
(mitral valve area, 1.1 cm2), moderate mitral regurgitation,
mild tricuspid regurgitation, mild to moderate aortic valve
regurgitation, and a round mass (6 × 5 mm) on the aortic
side of the non-coronary cusp (Fig. 1).
She admitted occasionally taking diuretics on her own
accord without medical recommendation, but denied
taking any anticoagulants during the past five years.
The diagnosis of RHD was clear, and the aortic valve
mass was considered to be an inflammatory mass, a
myxoma, or a fibroelastoma. Through median sternot-
omy, a cardiopulmonary bypass was established in the
Fig. 1 Transthoracic echocardiography. a, parasternal long-axis view shows a round mass (6 × 5 mm, arrow) on the aortic side of the non-coronary
cusp of the aortic valve in 2010. b, parasternal long-axis view shows a round mass (6 × 5 mm, arrow) on the aortic side of the non-coronary cusp of
the aortic valve in 2015. c, parasternal short-axis view shows a round mass (arrow) on the aortic side of the non-coronary cusp of the aortic valve in
2015. d, Apical 4 chamber view shows moderate mitral regurgitation
Fig. 2 Gross specimen of the resected mass and the non-coronary
cusp of the aortic valve
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conventional manner, and the mitral valve was found to
have grossly thickened and calcified leaflets with com-
missural fusion. The aortic valve was also thickened, and
a flower-like mass with multiple papillary fronds (8 ×
8 mm) was found on the aortic side of the non-coronary
cusp (Fig. 2). Because of the rheumatic change and aor-
tic regurgitation, the valve was judged to be unsuitable
for repair and was excised along with the tumor. The
mitral valve and aortic valve were both replaced with
St. Jude bileaflet mechanical valves. The tricuspid valve
was repaired; a bipolar radiofrequency ablation procedure
was performed to treat the atrial fibrillation. The case’s
postoperative course progressed smoothly, and TTE dem-
onstrated proper functioning of the prosthesis.
Histopathological examination of the resected tumor
revealed avascular papillomas with a single layer of endo-
cardial cells covering the papillary surface. The connective
tissue of PFE contains mature collagen with irregular elas-
tic fibers that are oriented longitudinally (Figs. 3 and 4).
The appearance of the mitral valve and aortic valve was
consistent with healed rheumatic valve disease.
Conclusions
PFE is a rare, benign cardiac neoplasm with an estimated
frequency of 0.021 % in autopsy series [3]. PFE is the
second most common type of benign tumor of the heart,
following myxoma [4]. PFE tumors are predominantly
located at valvular surfaces. The aortic valve is the most
commonly involved valve (44 %), followed by the mitral
valve (35 %), tricuspid valve (15 %), and pulmonary valve
(8 %). The other reported sites of PFE involvement are
the left atrium, atrial septum, right atrium, and right
ventricle [5].
The natural history of PFE has not been defined
because longitudinal follow-up studies have not been
performed. In this unusual case, the patient provides us
with the opportunity to learn about the natural history
of PFE indirectly. The tumor did not grow significantly
during the 5-year period, indicated that PFEs may be
generally slow-growing tumors.
Although the cause of PFE remains unknown, Kurup
and colleagues have noted that PFE could potentially be
related to cardiovascular intimal trauma. A history of
heart surgery or radiation to the chest may cause PFE
[6]. Regarding the patient in this report, the only poten-
tial endocardial irritation was RHD. However, further in-
vestigation is still needed to determine whether RHD
could cause PFE.
Most PEFs have been asymptomatic, and they have
usually been discovered incidentally at the time of echo-
cardiography, cardiac surgery, or autopsy [7]. Patients
with symptomatic PFE can experience a variety of symp-
toms. The clinical manifestations depend on many factors,
including the tumor's mobility, location, size, and ten-
dency for embolization. The main cause of symptoms is
thrombosis, such as cerebrovascular accident, or obstruc-
tion of the coronary artery, which results in cardiovascular
symptoms and events such as chest pain, myocardial in-
farction, and even sudden death (in severe cases) [8].
For symptomatic patients, especially for those with
mobile tumor, surgical resection with or without valve
replacement is recommended. These patients are at high
risk for thrombosis, which may be life-threatening,
whereas surgical removal poses low risk and the outcome
is excellent [9, 10]. However, surgical resection remains
controversial for patients without symptoms. Ngaage et al.
supported prompt surgical resection in asymptomatic PFE
cases because of potential life-threatening complications
[7]. On the other hand, Klarichhas et al. have reported that
PFEs not treated with surgery did not result in increased
mortality, but may be associated with higher risk of neu-
rologic events. Hence, for patients who are not surgical
candidates or refuse surgery, anticoagulation should be
Fig. 3 Hematoxylin and eosin stain (original magnification × 20)
Fig. 4 Verhoeff's elastic stain (original magnification × 20)
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considered to prevent clot formation on PFE surface,
while the patients should be closely followed-up [11].
During the 5-year period passed between her initial
presentation and the second admission, our patient did
not take anticoagulants and did not suffer any thrombosis,
which, however, does not mean that it is completely safe
to leave PFE without treatment. In our opinion, the better
treatment of choice may be surgery because it produces
good curative effects with very low risk of complica-
tions, while preventing serious disease consequences.
Still, further studies are required to determine the best
treatment for PFEs.
Consent
Written informed consent was obtained from the patient
for the publication of this case report and any accom-
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